RespireRx Pharmaceuticals Inc (RSPI)

[Jads14]

Since his employment, Dr. Stoll has guided this Company from a loss of about $1 million a year to a loss approaching $17 million last year. As might be expected, many of the stockholders who have purchased their stock on the open market have losses, and few have prospered. The Company has been kept afloat by multiple dilutive financings.

Jim, IMO this paragraph makes your post nothing but a personal vendetta post against Stoll. Guess you would have been much happier if the Company still had a 1M loss and didn't do any research at all. Most likely I have been in this stock longer than most on this board, since Nov. 1992 and yes it has been extremely frustating especially in the last few years but that is what happens in BioTechs. As for Stoll, has he been perfect, of course not but guess you don't remember or are not aware that when he took over, the Company had wasted all its funds on an ineffective CX-516 and was running on fumes with under 50K in cash, if that much. Does he have too many options, most likely but so what. If ampakine platform fails, he can have tens of millions and they will be worthless. On the other hand if CX-717 and other compounds are the real thing, it won't matter how many options he will have because price of stock will be unlimited and won't be effected one iota by the options.